Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-1-25
|
| pubmed:abstractText |
The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis. This randomised, double-blind, multicentre, three-arm study was conducted at 21 medical centres. A group of 292 nausea- and emesis-free patients with cancer, who had never had chemotherapy and were scheduled to receive at least 50 mg/m2 cisplatin, were given 3 mg granisetron i.v. in a 15-min infusion with or without 10 mg dexamethasone i.v. completed 5 min prior to high-dose cisplatin and 1 mg granisetron p.o. at +6 h and +12 h. Primary study end-points were control of emesis and nausea. Patients completed a self-report diary every 6 h for the first 24 h. At the end of the 24-h period, the patients who received dexamethasone had a significantly higher complete protection rate from emesis (64% compared to 39%) than those who received no steroid. Similarly, the dexamethasone-treated group had a significantly higher complete plus partial (0-2 emetic episodes) protection rate (84% compared to 64%). This study shows that dexamethasone markedly enhances the antiemetic efficacy of granisetron for acute-onset emesis in high-dose cisplatin chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiemetics,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Granisetron,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Antagonists
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0941-4355
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
307-12
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8520877-Acute Disease,
pubmed-meshheading:8520877-Adolescent,
pubmed-meshheading:8520877-Adult,
pubmed-meshheading:8520877-Antiemetics,
pubmed-meshheading:8520877-Antineoplastic Agents,
pubmed-meshheading:8520877-Canada,
pubmed-meshheading:8520877-Chi-Square Distribution,
pubmed-meshheading:8520877-Cisplatin,
pubmed-meshheading:8520877-Dexamethasone,
pubmed-meshheading:8520877-Double-Blind Method,
pubmed-meshheading:8520877-Drug Synergism,
pubmed-meshheading:8520877-Drug Therapy, Combination,
pubmed-meshheading:8520877-Female,
pubmed-meshheading:8520877-Granisetron,
pubmed-meshheading:8520877-Humans,
pubmed-meshheading:8520877-Linear Models,
pubmed-meshheading:8520877-Logistic Models,
pubmed-meshheading:8520877-Male,
pubmed-meshheading:8520877-Middle Aged,
pubmed-meshheading:8520877-Serotonin Antagonists,
pubmed-meshheading:8520877-Vomiting
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
|
| pubmed:affiliation |
Hematology-Oncology Division, Hôtel-Dieu de Montréal, Québec, Canada.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|